Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 692 participants.

Also called NCT04885218

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 692 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04885218
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04885218. Randomized; quadruple masking; primary purpose treatment. Start 2021-07-30 (actual); primary completion 2023-05-23 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia
Condition
Non-familial Hypercholesterolemia
Condition
Mixed Hyperlipidemia
Intervention (Drug)
SHR-1209 ;placebo
Intervention (Drug)
SHR-1209 ;placebo
Intervention (Drug)
SHR-1209 ;placebo
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04885218
Content hash
bc354ea6f62069c70fca5fe17df56e5f31ba3524bb82104b295ea654676eb71e